1. Home
  2. HIVE vs DRUG Comparison

HIVE vs DRUG Comparison

Compare HIVE & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HIVE

HIVE Digital Technologies Ltd.

HOLD

Current Price

$4.09

Market Cap

714.2M

Sector

N/A

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$82.58

Market Cap

707.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HIVE
DRUG
Founded
1987
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
714.2M
707.1M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
HIVE
DRUG
Price
$4.09
$82.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
6
Target Price
$6.44
$129.25
AVG Volume (30 Days)
23.9M
205.0K
Earning Date
02-17-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$169.51
N/A
Revenue Next Year
$39.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.60
$23.18
52 Week High
$7.84
$123.75

Technical Indicators

Market Signals
Indicator
HIVE
DRUG
Relative Strength Index (RSI) 73.65 50.80
Support Level $2.64 $79.55
Resistance Level $4.33 $84.29
Average True Range (ATR) 0.34 4.91
MACD 0.12 -0.47
Stochastic Oscillator 89.81 61.99

Price Performance

Historical Comparison
HIVE
DRUG

About HIVE HIVE Digital Technologies Ltd.

HIVE Digital Technologies Ltd is in the business of providing infrastructure solutions in the blockchain industry. It focuses on the mining and sale of digital currencies. Its geographical segments include Canada, Sweden, Iceland, Switzerland, and Bermuda, out of which the majority of the revenue comes from Bermuda.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: